Illumina prices 0.25% Convertible Senior Notes due 2016

Illumina, Inc. (NASDAQ:ILMN) today announced the pricing of $800 million principal amount of 0.25% Convertible Senior Notes due 2016 through offerings to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In connection with the offering, Illumina also granted the initial purchasers a 30-day option to purchase up to $120 million of additional notes. The offering is scheduled to close on March 18, 2011, subject to satisfaction of customary closing conditions.

The notes will pay interest semiannually at a rate of 0.25% per annum. The notes will be convertible under certain circumstances. Upon conversion, the holder of each note would receive, at our election, cash, shares of Illumina's common stock or a combination thereof, based on an initial conversion rate of 11.9687 shares of common stock per $1,000 principal amount of the notes, which is equal to an initial conversion price of approximately $83.55 per share.

Illumina intends to use up to $425 million of the net proceeds from this offering to purchase shares of its common stock in privately negotiated transactions concurrently with this offering. The company also intends to use between approximately $260 million and $390 million of the net proceeds of the offering to fund conversions of its currently outstanding convertible notes. Illumina intends to use the balance of the net proceeds for other general corporate purposes, which may include acquisitions and additional purchases of its common stock.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. Any offers of the securities will be made only by means of a private offering memorandum. The securities and the shares of Illumina common stock issuable upon conversion or exercise of the securities have not been, and will not be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2019, June 24). Illumina prices 0.25% Convertible Senior Notes due 2016. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20110315/Illumina-prices-02525-Convertible-Senior-Notes-due-2016.aspx.

  • MLA

    Illumina, Inc.. "Illumina prices 0.25% Convertible Senior Notes due 2016". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20110315/Illumina-prices-02525-Convertible-Senior-Notes-due-2016.aspx>.

  • Chicago

    Illumina, Inc.. "Illumina prices 0.25% Convertible Senior Notes due 2016". News-Medical. https://www.news-medical.net/news/20110315/Illumina-prices-02525-Convertible-Senior-Notes-due-2016.aspx. (accessed November 21, 2024).

  • Harvard

    Illumina, Inc.. 2019. Illumina prices 0.25% Convertible Senior Notes due 2016. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20110315/Illumina-prices-02525-Convertible-Senior-Notes-due-2016.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer